Business
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off M
About this update from Kura Oncology, Inc.
[{"type":"image","alt":"Kura Oncology, Inc.","displaySize":"","headline":null,"caption":"Kura Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PJRX2TqLyUcTZckqR2nKgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a","width":300,"height":157}},"lazy":false},{"type":"text","content":"Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy","length":145,"tagName":"p"},{"type":"text","content":"44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients ","length":124,"tagName":"p"},{"type":"text","content":"Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib","length":108,"tagName":"p"},{"type":"text","content":"Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off","length":118,"tagName":"p"},{"type":"text","content":"Manageable safety and tolerability profile in all RCC patients across multiple dose levels","length":90,"tagName":"p"},{"type":"text","content":"Virtual investor event today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST","length":104,"tagName":"p"},{"type":"text","content":"SAN DIEGO and PARIS, April 17, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib in the ongoing FIT-001 clinical trial (NCT06026410) of darlifarnib (KO-2806) in combination with cabozantinib. Results were presented at the 2026 International Kidney Cancer Symposium (IKCS): Europe in Paris, France.","length":550,"tagName":"p"},{"type":"text","content":"The analysis specifically evaluated patients with ccRCC who had previously received cabozantinib, a population that typically derives limited benefit from subsequent therapy. In this setting, the combination of darlif...